New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
05:32 EDTGILDGilead announces results from study of Sovaldi
Gilead Sciences announced results from an open-label clinical trial evaluating once-daily Sovaldi 400 mg tablets for the retreatment of chronic hepatitis C virus, or HCV, infection among patients who failed prior therapy. In Study GS-US-334-0109, patients with genotype 1 HCV infection received 12 weeks of treatment with once-daily Sovaldi plus weight-based ribavirin, or RBV, twice-daily and pegylated interferon. Patients in the study had failed prior regimens containing peg-IFN, RBV and an investigational NS3 protease inhibitor, with or without investigational direct-acting antivirals, or DAAs. 45% of patients had received more than one course of prior therapy, and 90 percent had at least one viral mutation associated with HCV NS3, NS5A or NS5B drug resistance. Among the 50 patients for whom sustained virologic response data was available 12 weeks after the end of treatment, 74% achieved SVR12. Additionally, 80% of patients with baseline resistance against two or more DAAs achieved SVR12. Sovaldi was well tolerated in Study GS-US-334-0109. The most common adverse events were consistent with the safety profiles of peg-IFN and/or RBV.
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent GILD news | >>
September 9, 2014
09:34 EDTGILDGilead recently started cutting Sovaldi pricing by 8%, says Cleveland Research
Subscribe for More Information
September 8, 2014
11:05 EDTGILDOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
09:40 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA YHOO BAC FB MSFT NFLX GILD MCD
08:48 EDTGILDGilead announces AMBITION study results in collaboration with Glaxo
Subscribe for More Information
September 5, 2014
16:45 EDTGILDMarket ends week little changed after mixed economic data
Subscribe for More Information
12:57 EDTGILDOn The Fly: Midday Wrap
Subscribe for More Information
12:04 EDTGILDGilead shares defended on today's weakness at Deutsche Bank
12:02 EDTGILDStocks with call strike movement; DAL GILD
Subscribe for More Information
11:47 EDTGILDOptions with increasing implied volatility
Subscribe for More Information
10:36 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
10:18 EDTGILDGilead shares defended at Bernstein
Subscribe for More Information
10:11 EDTGILDGilead slips after VP discusses low-cost Sovaldi for 80 countries
Subscribe for More Information
09:51 EDTGILDGilead drops, trades in wide range
Subscribe for More Information
09:50 EDTGILDGilead down 3.5% after reports of potential generic Sovaldi deal coming
09:49 EDTGILDGilead near deal for generic Sovaldi for developing countries, Bloomberg reports
Subscribe for More Information
09:43 EDTGILDGilead drops 6%, or $6.41, to $100.45
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA YHOO WFM SLW ABX GOOG FB BIDU
September 4, 2014
11:30 EDTGILDStocks with call strike movement; AAL GILD
American Airlines (AAL) November 44 call option implied volatility increased 6% to 39, Gilead (GILD) November 130 call option implied volatility decreased 5% to 40 according to IVolatility.
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
07:21 EDTGILDMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use